Progress in Transplantation最新文献

{"title":"One Editor's Tip on Publishing Outcomes of a Performance Improvement Project.","authors":"Rebecca P Winsett","doi":"10.1177/15269248231165328","DOIUrl":"https://doi.org/10.1177/15269248231165328","url":null,"abstract":"","PeriodicalId":20671,"journal":{"name":"Progress in Transplantation","volume":"33 2","pages":"107-109"},"PeriodicalIF":0.8,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9862810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perspectives on Donor-Derived Cell-Free DNA in Kidney Transplant Recipients with Systemic Lupus Erythematosus.","authors":"Michael D Williams, Vineet Gupta, Edie Y Chan, Oyedolamu Olaitan","doi":"10.1177/15269248231164175","DOIUrl":"https://doi.org/10.1177/15269248231164175","url":null,"abstract":"Many kidney transplant recipients undergo graft surveillance with AlloSure® donor-deived cell-free DNA (dd-cfDNA) (CareDx Inc.). Published data show that 75% of patients with stable grafts have dd-cfDNA less than 0.4%. In our experience, patients with systemic lupus erythematosus (SLE) have higher levels of dd-cfDNA, with fluctuations that cannot be explained by graft injury. We retrospectively evaluated 19 patients with SLE who underwent kidney transplantation (68% female, median age 40 years). Seventy-five dd-cfDNA values were obtained over a 3-year period; median= 0.39% (interquartile range: 0.21%-0.95%). Six allograft biopsies were performed during the study period (Table 1). Five showed no rejection, associated dd-cfDNA levels= 0.24%, 0.26%, 0.43%, 2.9%, 6.9%. One biopsy revealed antibody-mediated rejection (AMR), dd-cfDNA= 0.85%. The published median for AMR is 1.8%, and values less than 1% have a negative predictive value of 96%. Variations in dd-cfDNA can be used to detect rejection; relative change value (RCV) of >61% has been associated with high probability of graft injury. Two patients demonstrated significant variation in dd-cfDNA (Figure 1). The First patient increased from 0.5% to 2.9% (RCV= 480%) and the second patient rose from 0.31% to 6.9% (RCV= 2125%). Both patients had normal biopsies at the time of peak dd-cfDNA. Cell-free DNA (cfDNA) has been described in the pathophysiology of SLE and other inflammatory diseases. Elevations in cfDNA have been associated with SLE and have been proposed as a diagnostic biomarker. Systemic inflammation results in the release of cfDNA into circulation; fluctuations in dd-cfDNA may be related to lupus flares, or other SLE-related physiology, however, this does not appear to be the reason based on review of the patients’ charts. Published data doesn’t show clear correlation between disease flares and cfDNA levels in SLE. Because AlloSure is measured as a fraction (donor-derived/total circulating cfDNA), we investigated that changes in the total circulating cfDNA may lead to inappropriately high or low values in the setting of SLE. The total cfDNA values for our patients had no correlation between total cfDNA and the reported AlloSure values. Patients with large fluctuations in AlloSure had consistently low total cfDNA, suggesting that the source was the allograft. This requires attention since false positive values can lead to unnecessary biopsies. This small cohort of 6 biopsies could be outliers by chance, or by other factors not related to SLE. However, given the relationship between SLE and cfDNA, it is worth further investigation. Elevations in cfDNA are a hallmark of SLE, where both hematopoietic and nonhematopoietic cells contribute to cfDNA levels. Levels of cfDNA in circulation are affected by genetic and systemic factors. DNAse family of enzymes naturally degrade cfDNA and are essential for regulating the levels in circulation. Patients with single-nucleotide polymorphisms (SNPs) in nu","PeriodicalId":20671,"journal":{"name":"Progress in Transplantation","volume":"33 2","pages":"182-183"},"PeriodicalIF":0.8,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9862825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reassessing Geographic, Logistical, and Cold Ischemia Cutoffs in Liver Transplantation.","authors":"Stephanie Ohara,&nbsp;Blanca Lizaola-Mayo,&nbsp;Elizabeth Macdonough,&nbsp;Paige Morgan,&nbsp;Devika Das,&nbsp;Lena Egbert,&nbsp;Abigail Brooks,&nbsp;Amit K Mathur,&nbsp;Bashar Aqel,&nbsp;Kunam S Reddy,&nbsp;Caroline C Jadlowiec","doi":"10.1177/15269248231164169","DOIUrl":"https://doi.org/10.1177/15269248231164169","url":null,"abstract":"<p><strong>Introduction: </strong>Liver acceptance patterns vary significantly between transplant centers. Data pertaining to outcomes of livers declined by local and regional centers and allocated nationally remains limited.</p><p><strong>Project aim: </strong>The objective was to compare post-liver transplant outcomes between liver allografts transplanted as a result of national and local-regional allocation.</p><p><strong>Design: </strong>This was a retrospective evaluation of 109 nationally allocated liver allografts used for transplant by a single center. Outcomes of nationally allocated grafts were compared to standard allocation grafts (N  =  505) during the same period.</p><p><strong>Results: </strong>Recipients of nationally allocated grafts had lower model for end stage liver disease scores (17 vs 22, <i>P</i>  =  .001). Nationally allocated grafts were more likely to be post-cross clamp offers (29.4% vs 13.4%, <i>P</i>  =  .001) and have longer cold ischemia times (median hours 7.8 vs 5.5, <i>P</i>  =  .001). Early allograft dysfunction was common (54.1% vs 52.5%, <i>P</i>  =  .75) and did not impact hospital length of stay (median 5 vs 6 days, <i>P</i>  =  .89). There were no differences in biliary complications (<i>P</i>  =  .11). There were no differences in patient (<i>P</i>  =  .88) or graft survival (<i>P</i>  =  .35). In a multivariate model, after accounting for differences in cold ischemia time and posttransplant biliary complications, nationally allocated grafts were not associated with increased risk for graft loss (HR 0.9, 95% CI 0.4-1.8). Abnormal liver biopsy findings (33.0%) followed by donor donation after circulatory death status (22.9%) were the most common reasons for decline by local-regional centers.</p><p><strong>Conclusion: </strong>Despite longer cold ischemia times, patient and graft survival outcomes remain excellent and comparable to those seen from standard allocation grafts.</p>","PeriodicalId":20671,"journal":{"name":"Progress in Transplantation","volume":"33 2","pages":"168-174"},"PeriodicalIF":0.8,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9863321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Organ Transplantation Outcomes of Deceased Organ Donors in Organ Procurement Organization-Based Recovery Facilities Versus Acute-Care Hospitals.","authors":"Emily A Vail, Douglas E Schaubel, Peter L Abt, Niels D Martin, Peter P Reese, Mark D Neuman","doi":"10.1177/15269248231164176","DOIUrl":"10.1177/15269248231164176","url":null,"abstract":"<p><strong>Introduction: </strong>Recovery of donated organs at organ procurement organization (OPO)-based recovery facilities has been proposed to improve organ donation outcomes, but few data exist to characterize differences between facilities and acute-care hospitals.</p><p><strong>Research question: </strong>To compare donation outcomes between organ donors that underwent recovery procedures in OPO-based recovery facilities and hospitals.</p><p><strong>Design: </strong>Retrospective study of Organ Procurement and Transplantation Network data. From a population-based sample of deceased donors after brain death April 2017 to June 2021, donation outcomes were examined in 10 OPO regions with organ recovery facilities. Primary exposure was organ recovery procedure in an OPO-based organ recovery. Primary outcome was the number of organs transplanted per donor. Multivariable regression models were used to adjust for donor characteristics and managing OPO.</p><p><strong>Results: </strong>Among 5010 cohort donors, 2590 (51.7%) underwent recovery procedures in an OPO-based facility. Donors in facilities differed from those in hospitals, including recovery year, mechanisms of death, and some comorbid diseases. Donors in OPO-based facilities had higher total numbers of organs transplanted per donor (mean 3.5 [SD1.8] vs 3.3 [SD1.8]; adjusted mean difference 0.27, 95% confidence interval 0.18-0.36). Organ recovery at an OPO-based facility was also associated with more lungs, livers, and pancreases transplanted.</p><p><strong>Conclusion: </strong>Organ recovery procedures at OPO-based facilities were associated with more organs transplanted per donor than in hospitals. Increasing access to OPO-based organ recovery facilities may improve rates of organ transplantation from deceased organ donors, although further data are needed on other important donor management quality metrics.</p>","PeriodicalId":20671,"journal":{"name":"Progress in Transplantation","volume":"33 2","pages":"110-120"},"PeriodicalIF":0.6,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7b/cb/10.1177_15269248231164176.PMC10150267.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9507453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Eculizumab Use in Renal Transplant Recipients.","authors":"Kathryn Norville,&nbsp;Jenise Stephen,&nbsp;Carolyn Mead-Harvey,&nbsp;Rebecca Corey,&nbsp;Cassandra Votruba","doi":"10.1177/15269248231164163","DOIUrl":"https://doi.org/10.1177/15269248231164163","url":null,"abstract":"<p><p><b>Introduction:</b> Eculizumab is a monoclonal antibody that binds to complement protein C5, inhibiting complement-mediated thrombotic microangiopathy. It is approved for several indications including atypical hemolytic uremic syndrome. Additionally, eculizumab is used off-label for antibody-mediated rejection and C3 glomerulopathy in renal transplant recipients. Due to limited data available, the purpose of this study was to describe the use of eculizumab treatment in renal transplant recipients. <b>Design:</b> This retrospective single-center study evaluated the safety and efficacy of eculizumab for on- and off-label indications in renal transplant recipients. Adult renal transplant recipients receiving at least 1 dose of eculizumab posttransplant between October 2018 and September 2021 were included. The primary outcome evaluated was graft failure in patients treated with eculizumab. <b>Results:</b> Forty-seven patients were included in analysis. The median age at eculizumab initiation was 51 years [IQR 38-60], with 55% being female. Indications for eculizumab included atypical hemolytic uremic syndrome/thrombotic microangiopathy (63.8%), antibody-mediated rejection (27.7%), C3 glomerulopathy (4.3%), and other (4.3%). Graft failure occurred in 10 patients (21.3%) with a median of 2.4 weeks [IQR 0.5-23.3] from transplant to graft failure. At last follow-up (median 56.1 weeks), 44 (93.6%) patients were alive. After eculizumab initiation, renal function improved at 1 week, 1 month, and last follow-up. <b>Conclusion:</b> Eculizumab treatment demonstrated a benefit on graft and patient survival compared to reported incidence in thrombotic microangiopathy and antibody-mediated rejection. Due to the small sample size and retrospective design, further research is warranted to confirm these results.</p>","PeriodicalId":20671,"journal":{"name":"Progress in Transplantation","volume":"33 2","pages":"162-167"},"PeriodicalIF":0.8,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9862802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Goal-Directed Haemodynamic Therapy Improves Patient Outcomes in Kidney Transplantation.","authors":"Jez Fabes,&nbsp;Ammar Al Midani,&nbsp;Aman S Sarna,&nbsp;Dina H Hadi,&nbsp;Saqib A Naji,&nbsp;Neal R Banga,&nbsp;Gareth L Jones,&nbsp;Peter D Berry,&nbsp;Marc D Wittenberg","doi":"10.1177/15269248231164165","DOIUrl":"https://doi.org/10.1177/15269248231164165","url":null,"abstract":"<p><p><b>Introduction:</b> Kidney transplant graft function depends on optimised haemodynamics. However, high fluid volumes risk hypervolaemic complications. The Edwards Lifesciences ClearSight™ device permits fluid titration through markers of preload and beat-to-beat blood pressure monitoring. We evaluated the implementation of a novel goal-directed haemodynamic therapy protocol to determine whether patient outcomes had improved. <b>Design:</b> A retrospective evaluation of standard care versus goal-directed haemodynamic therapy in adults undergoing kidney transplantation was performed in a single centre between April 2016 and October 2019. Twenty-eight standard-of-care patients received intraoperative fixed-rate infusion and 28 patients received goal-directed haemodynamic therapy. The primary outcome was volume of fluid administered intraoperatively. Secondary outcomes included blood product and vasoactive drug exposure, graft and recipient outcomes. <b>Results:</b> Intraoperative fluid administered was significantly reduced in the goal-directed haemodynamic therapy cohort (4325 vs 2751 ml, <i>P</i> < .001). Exposure to vasopressor (67.9% vs 42.9%, <i>P</i> = .060) and blood products (17.9% vs 3.6%, <i>P</i> = .101) was unchanged. Immediate graft function (82.1% vs 75.0%, <i>P</i> = .515), dialysis requirement (14.3% vs 21.4%, <i>P</i> = .729) and creatinine changes post-operatively were unchanged. In the goal-directed haemodynamic therapy cohort, 1 patient had pulmonary oedema (3.6%) versus 21.4% in the standard cohort. Patients in the goal-directed haemodynamic therapy group were more likely to mobilise within 48 hours of surgery (number needed to treat = 3.5, <i>P</i> = .012). <b>Conclusions:</b> Protocolised goal-directed haemodynamic therapy in kidney transplantation was safe and may improve patient, graft, and surgical outcomes. Clinical trials assessing goal-directed approaches are needed.</p>","PeriodicalId":20671,"journal":{"name":"Progress in Transplantation","volume":"33 2","pages":"150-155"},"PeriodicalIF":0.8,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9501134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"External Validation of the United Kingdom Transplant Benefit Score in Australia and New Zealand.","authors":"Eunice G Lee,&nbsp;Marcos V Perini,&nbsp;Enes Makalic,&nbsp;Gabriel C Oniscu,&nbsp;Michael A Fink","doi":"10.1177/15269248221145047","DOIUrl":"https://doi.org/10.1177/15269248221145047","url":null,"abstract":"<p><p><b>Introduction:</b> In Australia and New Zealand, liver allocation is needs based (based on model for end-stage liver disease score). An alternative allocation system is a transplant benefit-based model. Transplant benefit is quantified by complex waitlist and transplant survival prediction models. <b>Research Questions:</b> To validate the UK transplant benefit score in an Australia and New Zealand population. <b>Design:</b> This study analyzed data on listings and transplants for chronic liver disease between 2009 and 2018, using the Australia and New Zealand Liver and Intestinal Transplant Registry. Excluded were variant syndromes, hepatocellular cancer, urgent listings, pediatric, living donor, and multi-organ listings and transplants. UK transplant benefit waitlist and transplant benefit score were calculated for listings and transplants, respectively. Outcomes were time to waitlist death and time to transplant failure. Calibration and discrimination were assessed with Kaplan-Meier analysis and C-statistics. <b>Results:</b> There were differences in the UK and Australia and New Zealand listing, transplant, and donor populations including older recipient age, higher recipient and donor body mass index, and higher incidence of hepatitis C in the Australia and New Zealand population. Waitlist scores were calculated for 2241 patients and transplant scores were calculated for 1755 patients. The waitlist model C-statistic at 5 years was 0.70 and the transplant model C-statistic was 0.56, with poor calibration of both models. <b>Conclusion:</b> The UK transplant benefit score model performed poorly, suggesting that UK benefit-based allocation would not improve overall outcomes in Australia and New Zealand. Generalizability of survival prediction models was limited by differences in transplant populations and practices.</p>","PeriodicalId":20671,"journal":{"name":"Progress in Transplantation","volume":"33 1","pages":"25-33"},"PeriodicalIF":0.8,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9085984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short Tutorial for Constructing Meaningful Tables Using AMA Style.","authors":"Rebecca P Winsett","doi":"10.1177/15269248231152923","DOIUrl":"https://doi.org/10.1177/15269248231152923","url":null,"abstract":"Constructing meaningful tables is important for any journal publication. This short tutorial is specific to the journal Progress in Transplantation that uses the AMA Manual of Style; however, the information may be useful for any presentation, internal report, or journal publication. The information is not meant to be comprehensive but to give pointers for authors to consider when developing tables to include in a manuscript. How often have we seen large comprehensive data crushed into a single table? The question from an editor or reader becomes: Is all the information pertinent to the manuscript submitted? Burying the important information within a large multirow, multi-column table often detracts from the major findings of the study. The tendency to overwhelm the reader with an excessive amount of data that does not pertain to the study’s purpose is tempting. It is often easier to include all data collected than to decide what variables are key to show that the study’s questions were answered. Tables are planned to match the manuscript.","PeriodicalId":20671,"journal":{"name":"Progress in Transplantation","volume":"33 1","pages":"3-4"},"PeriodicalIF":0.8,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10784584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Factors for First and Recurrent Fractures among Kidney Transplant Recipients.","authors":"Norman Atagu,&nbsp;Stefani Mihilli,&nbsp;Huong Thao Nguyen,&nbsp;Alicia Wu,&nbsp;Olusegun Famure,&nbsp;Yanhong Li,&nbsp;S Joseph Kim","doi":"10.1177/15269248221145034","DOIUrl":"https://doi.org/10.1177/15269248221145034","url":null,"abstract":"<p><p><b>Introduction:</b> Kidney transplantation is associated with increased risk of bone fracture. Current literature reports widely variable fracture burden and contains limited data on risk factors for recurrent fractures. <b>Methods:</b> The incidence of all and major osteoporotic fractures (hip, forearm, thoracolumbar, and proximal humerus) were assessed. The risk factors for first and recurrent fractures among 1285 Canadian kidney transplant recipients transplanted between January 1, 2004, and December 31, 2013 were also identified. <b>Results:</b> The 10-year cumulative incidence of all fractures and major osteoporotic fractures in this population was 27.1% (95% CI: 22.5, 32.4) and 17.8% (95% CI: 13.4, 23.5), respectively. On multivariable analysis, female sex (HR = 1.64 [95% CI: 1.20, 2.26]), history of fracture (HR = 1.54 [95% CI: 1.12, 2.11]), and pretransplant diabetes (HR = 1.85 [95% CI: 1.29, 2.65]) were recipient factors found to increase the risk for any first fracture posttransplant. These risk factors persist in analysis with the time origin 3-months posttransplant, where transplant age (HR = 1.01 [95% CI: 1.00, 1.03]) and increased time on pretransplant dialysis (HR = 1.06 [95% CI: 1.00, 1.12]) also emerge as risk factors for first fracture. On multivariable shared frailty model analysis, increased risk of recurrent fractures was associated with recipient female sex (HR = 1.74 [95% CI: 1.21, 2.51]) and history of diabetes (HR = 1.76 [95% CI: 1.17, 2.66]). <b>Discussion:</b> The results suggested that some risk factors for first fracture may not inform risk of recurrent fractures. As such, fracture risk should be assessed accordingly to optimize long-term care and implement preventive measures.</p>","PeriodicalId":20671,"journal":{"name":"Progress in Transplantation","volume":"33 1","pages":"16-24"},"PeriodicalIF":0.8,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a4/76/10.1177_15269248221145034.PMC9975818.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9077497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case Report of Excessive Inflammation After TACE That Mimicked Tumor Invasion of Adjacent Tissues.","authors":"Volkan Ince,&nbsp;Ibrahim Umar Garzali,&nbsp;Sertac Usta,&nbsp;Ramazan Kutlu,&nbsp;Sezai Yilmaz","doi":"10.1177/15269248221145037","DOIUrl":"https://doi.org/10.1177/15269248221145037","url":null,"abstract":"Liver transplantation is the most reliable treatment strategy for hepatocellular carcinoma (HCC) within certain selected criteria. Patients with HCC may not have access to liver donation at the appropriate time and this may result in fall out from the transplant list. To avoid this, bridging therapy has been recommended for patients with HCC to prevent progression of the tumor and to ensure that patients remain within the criteria of transplantation when the organ finally becomes available. Transcatheter arterial chemoembolization (TACE) is a commonly used bridging therapy in patients with HCC awaiting transplantation.","PeriodicalId":20671,"journal":{"name":"Progress in Transplantation","volume":"33 1","pages":"100-102"},"PeriodicalIF":0.8,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9091504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}